ARDS patients could find relief with a new technology invented at the University of Maryland, Baltimore.
Jeffrey Hasday, MD, and Paul Shapiro, PhD, are co-inventors of technology that is focused on treatments for inflammatory diseases, including acute respiratory distress syndrome, or ARDS, and has been licensed to GEn1E Lifesciences, a biotech company based in Silicon Valley. For their discovery, they have been recognized as the University of Maryland, Baltimore’s 2023 David J. Ramsay Entrepreneurs of the Year.
Hasday is the Dr. Herbert Berger Professor of Medicine and division head, pulmonary and critical care medicine, University of Maryland School of Medicine.
Shapiro is a professor of pharmaceutical sciences and associate dean of research and advanced graduate studies, University of Maryland School of Pharmacy.
#ARDS #universityofmaryland #medschool #pharmacyschool #biotech
